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Abstract
Neointimal hyperplasia of vascular smooth muscle cells (VSMC) plays a critical role in ath-
erosclerotic plaque formation and in-stent restenosis, but the underlying mechanisms are
still incompletely understood. We performed a proteomics study to identify novel signaling
molecules organizing the VSMC hyperplasia. The differential proteomics analysis in a bal-
loon-induced injury model of rat carotid artery revealed that the expressions of 44 proteins
are changed within 3 days post injury. The combination of cellular function assays and a
protein network analysis further demonstrated that 27 out of 44 proteins constitute key sig-
naling networks orchestrating the phenotypic change of VSMC from contractile to epithelial-
like synthetic. Among the list of proteins, the in vivo validation specifically revealed that six
proteins (Rab15, ITR, OLR1, PDHβ, PTPε) are positive regulators for VSMC hyperplasia. In
particular, the OLR1 played dual roles in the VSMC hyperplasia by directly mediating oxi-
dized LDL-induced monocyte adhesion via NF-κB activation and by assisting the PDGF-
induced proliferation/migration. Importantly, OLR1 and PDGFRβ were associated in close
proximity in the plasma membrane. Thus, this study elicits the protein network organizing
the phenotypic change of VSMC in the vascular injury diseases such as atherosclerosis
and discovers OLR1 as a novel molecular link between the proliferative and inflammatory
responses of VSMCs.
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Introduction
Atherosclerosis is an inflammatory vascular disease accompanying with the occlusion of the
arterial vessels. The early atherosclerotic lesions include sub-endothelial accumulations of
lipid-engorged macrophages (foam cells), which are represented as ‘fatty streak’ [1]. Fatty
streaks are not clinically harmful, but they can be the precursors of more advanced fibrous
and plaque-type lesions characterized by the accumulation of lipid-rich necrotic debris and
vascular smooth muscle cells (VSMCs). During the disease progression, the arterial wall
gradually thickens and hardens by the formation of atherosclerotic plaques. If the plaques
become fragile, they abruptly rupture and often cause myocardial infarction or stroke [2].
Consequently, atherosclerosis progresses for many decades and cannot easily be recognized
before the appearance of ischemic symptoms. Once the vascular narrowing is diagnosed, the
way to eliminate the plaques and dilate the occluded vessel area is the vascular intervention
by percutaneous transluminal angioplasty. However, the balloon-induced injury to the arte-
rial endothelium triggers the thrombotic activation of VSMC de-differentiation and hence
results in the dysplastic neointimal thickening, so-called in-stent restenosis. Such an in-stent
restenosis has been overcome by using cytotoxic drug-eluting stents but it is still responsible
for the clinical failures of vascular interventions [3, 4]. Overall, the SMC hyperproliferation is
the key step in the formation of both atherosclerotic plaques and neointimal thickening.
Given that the SMC hyperproliferation is triggered by multiple factors including the pro-
inflammatory factors [5–8], it is important to understand the complex cellular and molecular
communication networks orchestrating the hyperproliferation process.
Many attempts have been undertaken to identify the early diagnostic biomarkers and thera-
peutic targets for atherosclerosis in human samples or model animals [9]. For example, the
clinical data from a follow-up study of 3,209 participants in the Framingham Heart Study for
more than 7 years revealed several valuable biomarkers such as C-reactive protein, B-type
natriuretic peptide, renin, urinary albumin, homocysteine [10]. Plasma proteomics and meta-
bolomics experiments have also been aggressively conducted for many years to search for cir-
culating biomarkers that show a correlation with the atherosclerosis progression [11, 12].
Furthermore, an enormous number of studies have focused on therapeutic targets for athero-
sclerosis. Some of targets include paraoxonase [13], platelet-derived growth factor (PDGF) [7],
Fas ligand (CD95/Apo-1) [14], fatty acid-binding protein-4 [15], JNK2 [16], and netrin-1 [17].
Nonetheless, the above studies have described the problems owing to the inter-individual vari-
ability and inaccessibility of human tissues with vascular thickening. Therefore, we adapted a
proteomic strategy using the balloon-injured arterial vessels of genetically congenic rats and
validated the proteomes in human aortic VSMCs to search for the human-relevant candidates.
As results, we performed the quantitative and reproducible proteome analyses of more than
2,100 protein spots and identified nine novel candidates that positively regulate the VSMC
activities related to hyperproliferation. In particular, we determined a novel signaling role of
the oxidized LDL receptor-1 (OLR1) among the validated candidates in VSMCs.
Materials and Methods
Materials
Human aortic SMCs (HASMC) were purchased from Clonetics-Bio Whittaker (Venders,
Belgium) and grown on 0.1% gelatin-coated plate at 37°C in a humidified incubator contain-
ing 5% CO2 in Smooth Muscle Cell Basal Medium (SmBM) SingleQuotes with 10% fetal
bovine serum (FBS) and full supplements (Clonetics-BioWhittaker; Cat no. cc-4149). They
were used for the study at passage number 7 showing active growth. The human monocytic
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cell line U937 was obtained from American Type Culture Collection (Rockville, MD) and
maintained in culture medium RPMI 1640 (WelGENE lnc) supplemented with 10% FBS
(HyClone).
For quantitative real-time PCR (qPCR), the primers specific for rat Rab15 (QT01614088), rat
ITR (QT01608635), rat OLR1 (QT00191254), rat PDHB (QT00431263), rat PTPRE
(QT02335606), rat UCHL1 (QT01081080), rat PRKACA (QT01588629), and rat VDAC1
(QT00190561) were purchased fromQiagen. Primers for rat β-actin reference gene were (sense)
5’- TGGATCAGCAAGCAGGAGTAT-3’ and (antisense) 5’-GCATTTGCGGTGGCAGAT3’.
Primers for rat 18S rRNA reference gene were (sense) 5’-GGCCGTTCTTAGTTGGTGGAGCG-
3’ and (antisense) 5’-CTGAACGCCACTTGTCCCTC-3’.
Anti-tubulin antibody was purchased from Sigma-Aldrich. Anti-PDI, enolase-1, Lamin B,
ERK2, GAPDH, IκBα (C-21), PDGFR-β (M-20) and VDAC1 antibodies were purchased from
Santa Cruz Biotechnology. Anti-PTPε antibodies for human immunohistochemistry staining
were purchased from Atlas Antibodies (Stockholm, Sweden). Anti-PCNA, β-actin, ERK
(pT202/pY204) and IκBα (pSer32/36) antibodies were purchased from Cell Signaling Technol-
ogy. Anti-phosphotyrosine (4G10) and UCHL1 antibodies and PDGF-BB were from Upstate
Biotechnology. Anti-OLR1 and transferrin receptor antibodies were purchased from R&D sys-
tems. Anti-CD18 antibody was purchased from BD Bioscience. Rabbit polyclonal antibody
against PDGFRβ (pY857) was produced as previously described [18].
Minimally oxidized low-density lipoproteins (mmLDLs) were purchased from KALEN
Biomedical (Maryland, USA). DuoLink In Situ Fluorescence reagents were purchased from
Sigma-Aldrich.
Animal study
Animal experiments using Sprague-Dawley rats were granted by approval of the Institutional
Animal Care and Use Committee (IACUC) of Ewha Womans University and conformed to
the Guide for Care and Use of Laboratory Animals published by the US National Institutes of
Health (The National Academies Press, 8th Edition, 2011). All surgical procedures were per-
formed under inhalational anesthesia with isoflurane gas (N2O:O2/70%:30%), and all efforts
were made to minimize suffering. The ten-week-old male Sprague-Dawley rats (Charles River,
U.S.A.) were for used for a balloon-induced carotid injury model. The animal experiments for
main and supplementary figures were repeated twice. The detailed animal numbers in experi-
mental groups are described in the figure legends.
Balloon-induced injury of rat carotid artery
The ten-week-old male Sprague-Dawley rats were used for a balloon-induced injury model of
rat carotid artery. A balloon injury was created using an infiltrated 2F Fogarty balloon embo-
lectomy catheter in the left common carotid artery, as previously described [19]: The rats were
anaesthetized by inhalation of isoflurane gas (N2O:O2/70%:30%); the left external carotid
artery was exposed; and its branches were electro-coagulated. A catheter was pushed 1 cm
through the transverse arteriotomy of the external carotid artery, and the endothelial denuda-
tion was achieved by three passes along the common carotid artery. After removal of the cathe-
ter, the punched area was sealed and the clapped common carotid artery was opened to resume
the blood flow. After the surgical operation, the rats were recovered in the cages for various
times (zero, 0.75, 3, 5, and 7 days for proteomics study; 10 days for in vivo validation of selected
proteins). The sham operation was used as a control for zero time.
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Subcellular fractionation of carotid arteries
After rats were anaesthetized by inhalation of isoflurane gas (N2O:O2/70%:30%) and per-
fused with heparinized saline, the balloon-injured left carotid arteries were removed. The
arteries (8 rats per group) were immediately washed in cold saline to remove erythrocytes
and then minced with a razor. If necessary, the excess blood was flushed out from the lumen
area of arteries by 26 gauge syringe. The minced carotid arteries were resuspended in 1 ml of
hypotonic buffer (10 mM HEPES pH 7.5, 2 mMMgCl2, 25 mM KCl, 0.5 mM EDTA, 0.5 mM
EGTA, 1 mM DTT, 1 mM AEBSF, 5 μg/ml Leupeptin and Aprotinin, 1 mM Na3VO4, 5 mM
NaF) and placed on ice for 30 min. Arteries were gently homogenized with 25 strokes in
Dounce homogenizer and the homogenates were centrifuges twice at 750 x g for 10 min. The
first pellets were kept on ice for nuclei preparation. The supernatants were further centri-
fuged at 100,000 x g for 1 hr with a table top ultracentrifuge (Beckman Coulter). The result-
ing second pellet and supernatant (S-100) were designated as heavy/light membrane and
cytosolic fractions, respectively. For isolation of pure nuclei, the first pellets were resus-
pended in 1 ml detergent-containing hypotonic buffer (10 mM Hepes pH 7.5, 2 mMMgCl2,
10 mM KCl, 0.2% NP-40, 0.5 mM EDTA, 0.5 mM EGTA, 1 mM AEBSF, 5μg/ml Leupeptin
and Aprotinin, 1 mM Na3VO4, 5 mM NaF) and then disrupted by passing 10 times through
22-guage needle. After repeating this process three times, the resulting pellets were desig-
nated as nuclei fraction. The S-100 cytosolic fraction was concentrated by TCA precipitation.
The protein precipitates were rinsed with acetone twice to remove residual TCA solution
and subjected to the proteome analyses. Finally, the protein-containing pellets of the sepa-
rated fractions were dissolved in a lysis solution containing 8 M urea, 4% CHAPS, 2% IPG
buffer, and protease inhibitor and subjected to the following 2D-DIGE analyses. The protein
concentration was determined by a Bradford assay.
Two dimensional difference gel electrophoresis (2D-DIGE)
The two consecutive samples among 5 serial time points were differently labeled with the N-
hydroxysuccinimidyl ester forms of Cy3 and Cy5 fluorescent dyes in a pair. The equal amount
of protein (10 μg) from five serial samples were pooled and labeled with Cy2 fluorescent dye as
an internal standard. For dye labeling, 50 μg of protein was resuspended in 15~20 μl of labeling
buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, pH 8.5) and reacted with 400 pmol of
each dye for 30 min on ice in the dark. The reaction was then quenched with the addition of 10
mM lysine (1μl for each reaction). The Cy3-labeled sample (50 μg), Cy5-labeled sample
(50 μg), and the Cy2-labeled internal standard (50 μg) were combined and mixed with an equal
volume of 2 × rehydration buffer (7 M urea, 2 M thiourea, 4% CHAPS, 130 mMDTT, 2% pH
4–7 IPG buffer or pH 3–10 NL IPG buffer) in a final volume of 120 μl. Then, the samples were
subjected to the first-dimensional isoelectrofocusing on 13-cm pH 4–7 or pH 3–10 NL IPG
strips (Amersham Biosciences/GE Healthcare). The second-dimension was performed on 10%
polyacrylamide denaturing gels.
The fluorescence images of DIGE gels were taken by a Typhoon 9400 variable mode imager
with at 100-μm resolution (Amersham Biosciences/GE Healthcare) and analyzed with the
DeCyder version 6.5 suite of software tools (Amersham Biosciences/GE Healthcare). After the
fluorescence analysis, the 2D-DIGE gels were silver-stained and merged with the correspond-
ing fluorescence images for excision of protein spots showing differential expression. The
excised spots were subjected to the mass spectrometry following in-gel trypsin digestion as pre-
viously described [20].
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Mass spectrometry
The identification of protein spots was performed by MALDI-TOF or ESI-MS/MS. For MAL-
DI-TOF, the tryptic digests were reconstituted in 10 μl of 0.1% trifluoroacetic acid and treated
with ZipTips containing a C18 resin (Millipore) according to the manufacturer's instructions.
The peptides were dissolved in 2 μl of matrix solution (1% w/v of α-cyano-4-hydroxycinnamic
acid (CHCA) in 50% acetonitrile, 0.1% v/v TFA) and the aliquots (0.5 μl) were applied twice to
a target disk and dried. Mass Spectra were obtained using an Applied Biosystems Voyager-
DETM STR workstation (Foster City, CA, USA). The raw spectrum were opened in Voyager
Data Explorer software (version 4.6) and calibrated with two peptides resulting from trypsin
autolysis (m/z 842.5100 and 2211.1046). Monoisotopic peptide masses only were assigned for
searching, the peak detection threshold was manually adjusted over the background, and the
peak list was copied to Mascot public interface and searched against rat SwissProt database
(version 49.0, released February 7, 2006, 17548 entries) using the following parameters: trypsin
as digest enzyme, two possible missed cleavages, acetylation (K), pyroglu (N-term E, Q), oxida-
tion (M), phosphorylation (S,T,Y), propionamidation or cabamidomethylation (C) as variable
modification, and peptide tolerance of 20 ppm. Results were scored using probability-based
Mowse score (Protein score is -10 × log(p) where p is the probability that the observed match is
a random event. The protein score greater than 50 was determined to be significant (p<0.05).
The MS/MS analysis for peptide sequencing was done in nano flow reversed-phased HPLC/
ESI/MS with a mass spectrometer (Q-TOF Ultima global, Waters Co. UK). The tryptic digests
(5 μl) were dissolved in buffer A (water/ACN/formic acid; 95:5:0.2, v/v) and injected onto a C18
reversed-phase 75 μm i. d. x 150 mm analytical column (3 μm particle size, Atlantis dC18,
Waters) with an integrated electrospray ionization SilicaTip (± 10 μm, New Objective, USA).
The peptides were desalted in a line prior to separation using a trap column (i.d. 0.35 x 50 mm,
OPTI-PAK C18, Waters) cartridge and eluted by a linear gradient of 5–80% buffer B (water/
ACN/formic acid; 5:95:0.2, v/v) over 120 min. The flow rate was set to 200 nl/min by a split/split-
less inlet and the capillary voltage (3.0 kV) was applied to the HPLCmobile phase before spray-
ing. Chromatography was performed online using the instrument’s control software MassLinx of
Q-TOF Ultima global (Version 4.0, Waters Co. U.K.). The mass spectrometer was programmed
to record scan cycles composed of one MS scan followed byMS/MS scans of the three most
abundant ions in eachMS scan within 10s window. The acquired spectra were automatically pro-
cessed using ProteinLynx Global Server data processing software (version 2.1, Waters Co.UK)
and matched against amino acid sequences in rat SwissProt database (version 50.8. released Sep-
tember 11, 2008, 21455 entries) using Mascot search (version 2.1.03 Matrix Science, London,
UK) and MODi (Korea, http://modi.uos.ac.kr/modi/). The search parameters were as follow: 0.3
Da tolerance for peptide and fragment ions; digestion with trypsin with up to two missed cleav-
age allowed, acetylation (K), deamidation (N,Q), methylation (K), dimethylation (K), pyroglu
(N-term E, Q), oxidation (M), phosphorylation (S,T,Y), ubiquitination (K), propionamidation or
cabamidomethylation (C) were set as a variable modification but not fixed modification. Results
were scored using probability-based Mowse score (Protein score is -10 × log(p) where p is the
probability that the observed match is a randem event. The protein score greater than 50 was
determined to be significant (p<0.05). In addition, a minimum total score of 50, comprising at
least a peptide match of ion score more than 20, was arbitrarily set as threshold for acceptance.
All reported assignments were verified by automatic and manual interpretation of spectra.
Western blotting
The protein content of tissue or cell extracts was quantified using the Bradford reagent (Bio-
Rad). The samples were mixed with 5x Laemmli sample buffer and boiled for 5 min. The boiled
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samples (15 μg protein) were separated on 10% SDS polyacrylamide gels and then transferred
to nitrocellulose membranes. The membranes were incubated with a blocking buffer (5% non-
fat milk or 1% BSA in Tris-buffered saline containing 0.5% Tween-20) for 1 hr with rocking at
room temperature. The blots were incubated with the indicated primary antibodies in the
blocking buffer at 4°C overnight. After washing three times with TBST, the blots were incu-
bated with horseradish peroxidase-conjugated sheep anti-mouse immunoglobulin G (IgG;
1:5000) or with goat anti-rabbit IgG (1:3000) for 1 hr at room temperature. The specific
immune-reactive protein bands were visualized using Amersham ECL detection system (GE
healthcare).
Proliferation and migration assays
For proliferation assay, the HASMCs were seeded at a density of 4000 cells/well in a final vol-
ume of 100 μl onto 96-well plates containing siRNA-siPORT NeoFX reagent premixes (reverse
transfection, Ambion). After a 24-hr transfection, the cells were serum-starved for 18 hr, and
then stimulated with PDGF-BB (25 ng/ml, Upstate Biotenology Inc) in the SmBM basal
medium for an additional 24 hr. The extent of cell proliferation was measured using a WST-1
cell proliferation assay kit (Roche Diagnostics, USA). The cell number was expressed as light
absorbance at 450 nm, which was averaged from triplicate wells after subtracting the turbidity
at 600 nm.
The migration assay was performed in 24-well Transwell culture chambers (Costar; 8-μm
pore size). The bottom of the filter was coated with gelatin B (1 mg/ml) and air-dried for 1 hr.
HASMCs (6 × 103 cells/ml) were added to the upper chambers, which contained transfection
premixes. After a 24-hr transfection, the transfected cells were serum-starved overnight. The
SmBM basal media containing PDGF-BB (25 ng/ml) and 0.5% BSA were added to the bottom
chambers. The upper chamber wells were filled with SmBM basal media containing 0.5% BSA.
Transwell chambers were incubated at 37°C/5% CO2 for 8 hr. After incubation, the non-
migrated cells were removed from the top of the filters, and the cells that migrated onto the
bottom of filters were fixed and stained with 0.6% hematoxylin and 0.5% eosin. The stained
cells were photographed and counted. The number of migrating cells was averaged from tripli-
cate wells.
Monocyte adhesion assay
U937 monocytes (1×106 cells/ml) were incubated in the presence of IFN-γ (50 μg/ml) and LPS
(100 ng/ml) for 24 hr. Separately, HASMCs were seeded on at a density of 2×103 cells/well in a
final volume of 100 μl into the 96-well plates containing 20 μl transfection premixes as
described in the proliferation assay. After 48 hr, the cells were stimulated with OxLDL (100 μg/
ml) or TNF-α (10 ng/ml) for further 24 hr. U937 cells were labeled with 4 μM tetramethylrho-
damine ethyl ester, perchlorate (T-669, Molecular Probes, Eugene, OR) for 30 min. The labeled
U937 cells (1×105 cells/well) were added on stimulated HASMC and incubated for 1 hr. Non-
adherent cells were removed by washing three times with PBS. The adherent U937 cells on the
HASMC surface were identified in 2 randomly-selected microscopic areas under inverted
microscope (Axiovert 200 Basic standard, Zeiss, Germany) and then counted by Phoretix 2D
Evolution (Nonlinear Dynamics Ltd, USA)
Network analysis
Two networks were first generated for the 25 proteins using 1) ‘Manual Expand’ (ME) algo-
rithm with the two maximum number of interactions and 2) ‘Direct Interaction’ (DI) algo-
rithm in MetaCore(ver 6.13) [21]. These two networks were then combined to generate an
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initial network model. To clarify the relationships among the 25 proteins, the nodes not con-
tributing to functional connections between the 25 proteins were removed from the network
model as follows. We identified gene ontology biological processes (GOBPs) significantly
(P<0.01) represented by the proteins in the initial network using DAVID software [22] and
GO Trimming (ver 2.0) [23] that removes redundant GOBPs. We then pruned the nodes not
involved in these GOBPs. Also, among the proteins in the same protein family, we pruned the
proteins that do not interact with the 25 protein seeds. After computing the number of interac-
tions with the 25 proteins (K) for every node, we pruned transcription factors with K<5. The
resulting final network was visualized using Cytoscape (v. 2.8.1) [24]. The nodes involved in
similar or same GOBPs and KEGG pathways were grouped into the same modules, each of
which was named by the corresponding GOBP or KEGG pathway.
Catheter-mediated intramural delivery of siRNAs into carotid artery
The rat-specific siRNA SMART pools (Thermo Scientific Dharmacon, 200 nM) were premixed
with siPORTTM NeoFX reagent following the manufacturer’s instructions (Ambion). The com-
mon carotid arteries were balloon-injured and briefly washed with Opti-MEM. The transfec-
tion pre-mix (200 μl) was then administered through the catheter with punctured balloon [19,
25]. The vessel was incubated for 15 min for the efficient transfection and then ligated. A fluo-
rescent dye-conjugated control siRNA (siGLO-Red, Dharmacon) was used for optimizing the
intramural transfection efficiency.
Histological analysis
Rats were anesthetized and the common carotid arteries were excised after transcardiac perfu-
sion-fixation with heparinized saline containing 3.7% formaldehyde. The vessels were paraffin
embedded and sectioned by rotary microtome (Leica RM2255). The two serial tissue sections
(4 μm in thickness) were obtained from the middle area of common carotid arteries and
stained with haematoxylin and eosin (HE). The luminal, internal elastic laminal, and external
elastic laminal areas were measured using NIH Image v1.62. The intimal and medial areas were
determined by subtraction of the luminal area from the internal elastic area and by subtraction
of the internal elastic area from the external elastic area. The values from two serial sections per
rat were averaged for analysis.
Preparation of normal arterial vessel sample
With informed consent, human mammary arteries were harvested from a patient who under-
went a mastectomy in accordance with the guidelines of the Committee on Ethics of Ewha
womans University. The isolated artery tissues were immediately embedded in OCT medium
and frozen at -80°C. The frozen tissue sections (7 μm in thickness) were prepared and used as
normal arterial control for immunohistochemistry.
Statistical analysis
Data were analyzed with either Student t-test for comparisons between two groups or one-way
ANOVA with Tukey’s ‘honestly significant difference’ post hoc test for multiple groups (SPSS
12.0K for Windows, SPSS, Chicago, IL, USA). A P< 0.05 was considered to be statistically
significant.
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Results
Balloon-induced injury induces a significant proteome change in rat
carotid vessels
The physical injury of arterial vessels using a balloon embolectomy catheter causes the dysplas-
tic neointimal thickening. This process involves the thrombosis-induced activation of VSMC
hyperplasia following endothelial denudation. Experimentally, a balloon-induced injury of rat
carotid artery is the best animal model that shows typical neointimal thickening within 10 days
post injury. It is cost-effective and allows a reasonable amount of samples for histological and
biochemical analyses because rat common carotid arteries are relatively long unbranched arte-
rial vessels. It is significant that this model also represents the atherosclerotic plaque formation
during which the VSMCs proliferates via a phenotypic change and form a fibrous cap in the
plaque lesion [1]. As previously shown [26], the balloon injury induced a gradual increase of
neointimal thickness in the lumen side of injured lesion (S1 Fig). Based on this kinetics, we
chose the time points (0–7 days post injury) relevant to VSMC proliferation via a phenotypic
change (contractile to synthetic) and then performed the two-dimensional differential gel elec-
trophoresis (2D-DIGE) for quantitative proteome analysis (Fig 1A and S2A Fig). The tissue
extracts were fractionated into three subcellular compartments (heavy/light membranes,
nuclei, and cytosol) in order to maximize the number of proteins to be analyzed in 2D-DIGE
(Fig 1B). As results, we analyzed more than 2,100 protein spots and found that 140 spots show
a significant expression change. Among spots showing the differential expression the forty four
proteins were identified by mass spectrometry (S1 Table and S2B–S2E Fig). It is noteworthy
that most of the nuclei proteins identified (~80%) showed a transient change in protein level
during recovery after balloon-induced injury; whereas, most proteins identified in membrane
and cytosolic fractions showed a gradual increase or decrease. The differential expression of
the identified proteins was again confirmed by immunoblotting with specific antibodies (Fig
1C), supporting that the proteome analyses were quantitative and accurate.
Human VSMC-relevant candidate proteins are selected by in vitro cell
assays
A general concern has emerged whereby the expression pattern of a particular gene of interest
can be different among the species. Thus, we decided to validate the cellular function of the
rodent-origin 43 candidate proteins, except Ba1 (spot: M2), in human aortic VSMCs
(HASMCs). The expression of each target gene was knocked down in the HASMCs by a reverse
transfection with a mixture of four specific small interfering RNAs (siRNAs), as described in
Materials and Methods (S2 Table). The high in vitro transfection efficiency was tested using a
red fluorescent siGLO probe. The proliferation and chemotactic migration of aortic VSMCs
were induced by PDGF-BB, which is a major VSMC growth factor; whereas, the monocyte
adhesion to VSMCs was induced by tumor necrosis factor-α (TNF-α), a major pro-inflamma-
tory cytokine. Both PDGF-BB and TNF-α are presumed to be produced mainly by macro-
phages in the atherosclerotic and balloon-injured lesions. From the extensive cell-based assays
performed in triplicate, we found that depletion of 27 proteins showed positive and negative
effects on one or more cellular activities; whereas, the depletion of residual 16 proteins had no
effect on all three cellular activities (Fig 2 and Table 1). It supposed that the latter false positive
proteins could be identified due possibly to the use of entire carotid vessel, including neointi-
mal and medial layers, for proteomics analysis. Among those showing the effector activity,
some of the candidate proteins were likely to be the master regulator in diverse cellular activi-
ties of human VSMCs. For example, the knockdown of PKAα catalytic subunit (PKACA)
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increased all three cellular activities; whereas, the knockdown of six proteins (Rab-15, Lactate
dehydrogenase B, Intimal thickness-related receptor (ITR/GPR180), Oxidized LDL receptor
(OLR1/LOX-1), and IL-12 receptor β2 (IL-12Rβ2)) significantly reduced three types of VSMC
activities. It is noteworthy that the latter 5 positive effector proteins could be targeted for pre-
vention of typical vascular SMC hyperplasia. Furthermore, we performed in-depth validation
of two candidates, ITR and PKACA, as representative positive and negative effectors, respec-
tively. RT-PCR showed the almost perfect knockdown of two gene expressions (S3A Fig). The
in vitro cell assays confirmed that the depletion of ITR expression consistently reduced the
PDGF-induced proliferation and chemotactic migration of human SMCs and inhibited the
Fig 1. Analysis of proteome change in the injured arterial vessel. (A) Schematic presentation of quantitative proteome analyses. The rat carotid vessels
were injured with a balloon catheter, as described in the Materials and Methods. The tissue homogenates of the injured rat carotids were fractionated into
three subcellular fractions, labeled with fluorescent dyes (Cy2, Cy3, and Cy5), and separated on the 2D gels. ICA, internal carotid artery; ECA, external
carotid artery; CCA, common carotid artery; LM, light membrane; HM, heavy membrane. (B) Quality control of the subcellular fractionations used in the
2D-DIGE analysis. The subcellular fractionation of the tissue homogenates was performed by differential centrifugation. Lamin B, β-actin, and transferrin
receptor (TfR) were used as subcellular markers for nuclei, membranes, and cytosol (S-100), respectively. A representative immunoblot is shown (n = 3). (C)
Western blot analysis of protein candidates selected from 2D-DIGE analyses. The differential expression of the indicated proteins during the recovery time
after injury was evaluated by immunoblotting with specific antibodies. A representative blot is shown (n = 3). The corresponding spot numbers are indicated
in parallel. GS, glutamine synthetase; PDI, protein disulfide isomerase; PCNA, proliferating cell nuclear antigen; UCHL1, ubiquitin carboxy-terminal
hydrolase L1; PKACA, protein kinase A alpha catalytic subunit; VDAC1, voltage-dependent anion channel-1.
doi:10.1371/journal.pone.0133845.g001
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Fig 2. In vitro cell assays for functional validation of differentially-expressed protein candidates in
HASMCs. HASMCs were transfected with the specific siRNAmixes listed in the S1 Table for 18 hr and
stimulated with PDGF-BB (25 ng/ml) or TNF-α (10 ng/ml). Each experiment was performed in triplicate and
the data in the graph are means ± S.D. of fold changes from three independent experiments (*P<0.02,
**P<0.002). UT, untreated; C, control siRNA-transfected cells; S, cytosolic S-100; N, nuclei; M, membrane.
The number designated each bar corresponds to the spot number.
doi:10.1371/journal.pone.0133845.g002
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monocyte adhesion to human SMCs pre-activated by TNF-α treatment (S3B Fig). In contrast,
the depletion of PKACA markedly augmented those SMC activities (S3C Fig). Collectively, the
data indicate that the in vitro cell-based validation using human VSMCs effectively filtered out
human-irrelevant false-positives among a number of candidate proteins screened from rodent
disease model.
Protein interaction network elicits novel proteins involved in the SMC
hyperplasia
To understand a functional correlation among 27 selected proteins, we then constructed a net-
work model showing the map of the protein-protein or protein-DNA interactions (Fig 3). ITR
and membrane-bound C2 domain-containing protein were omitted due to the lack of the
Fig 3. A networkmodel of proteins related to the VSMC hyperplasia in vascular injury response. The nodes with the same GOBPs or KEGG pathways
were grouped into the samemodules, each of which was named by the corresponding GOBP or KEGG pathway. The 25 proteins are denoted by the
diamond nodes. Inner and outer node colors represent the changes in abundances of the 25 proteins at 18 hr and 7 days after balloon-induced injury,
respectively. Color bar, gradient of log2-fold-changes. Red and green colors represent up- and down-regulation of the proteins, whereas yellow represents
no changes in abundance. White circular nodes with gray boundaries denote the proteins added to connect the 25 proteins. Black and blue edges represent
protein-protein and protein-DNA interactions, respectively.
doi:10.1371/journal.pone.0133845.g003
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Table 1. List of proteins showing differential expression in the injured carotid artery and their cellular activities in VSMCs.
Spot Gene Protein SwissProt Loss-of-expression effect
ID ID Name Assession Number Proliferation Migration Adhesion
S1 DNM1 Dynamin O35303 - - -
S2 HSPCB heat shock protein 90-beta P34058 - - -
S3 AFP alpha-fetoprotein P02773 - - -
S4 CRMP1 Dihydropyrimidinase related protein Q9JMG8 - - -
S5 GRP58 Protein disulﬁde-isomerase P11598 - - -
S6 GC Vitamin D-binding protein precursor P04276 - - -
S7 ENO1 Enolase-1,alpha P04764 - - -
S10 GLUL Glutamine synthase P09606 - - -
S13 ALDOC Aldolase C P09117 - - -
S17 NSF N-ethylmaleimide sensitive factor O88960 - - -
S18 LGALS1 Galectin-1 P11762 - - -
N1 NEO1 Unnamed protein product P97603 - - -
N8 YWHAE 14-3-3 epsilon P62260 - - -
M8 PRELP PRELP Q9EQP5 - - -
M10 ANXA5 Annexin A5 P14668 - - -
M13 STOM stomatin Q5XI04 - - -
S12 LDHB Lactate dehydrogenase B P42123 5 5 5
S15 RAB15 Rab-15 P35289 5 5 5
N5 OLR1 Oxidased low density lipoprotein receptor O70156 5 5 5
N7 ITR Intima thickness-related receptor Q5XIJ2 5 5 5
M15 IL12RB2 IL-12 receptor beta 2 F1LRH7 5 5 5
N2 LMNA Lamin A P48679 5 5 -
N6 PDHB Pyruvate dehydrogenase beta P49432 5 5 -
M4 PTPRE Epsilon tyrosine phosphatase B2GV87 5 5 -
M12 ANXA2 Calpatin 1 heavy chain(annexin A2) Q07936 5 - 5
S8 SERPINA1 serine protease inhibitor 2c P17475 5 - -
S14 RAB3D Rab-16 Q63942 5 - -
N9 PCNA PCNA P04961 5 - -
M3 PLG plasminogen Q01177 5 - -
M6 CCT5 CCT(chaperonin containing TCP-1) epsilon subunit Q68FQ0 5 - -
M7 AP2M1 Adaptor protein complex AP-2,mul P84092 5 - -
S11 MDH1 Malate dehydrogenase-like enzyme P04636 - 5 -
M16 CYCS Cytocrome C,somatic P62898 - 5 -
M9 PRKACA PKA alpha catalytic subunit P27791 ▲ ▲ ▲
N10 UCHL1 UCH-L1 Q00981 ▲ ▲ -
M5 ANXA6 Annexin A6 P48037 ▲ ▲ -
M11 ANXA1 Lipocortin 1 (Annexin A1) P07150 ▲ ▲ -
M14 VDAC1 VDAC-1 Q9Z2L0 ▲ ▲ -
S16 HSPB1 heat shock 27 P42930 ▲ - -
N3 GTF2F1 general transcription factor IIF polypeptide 1 Q6AY96 - ▲ -
N4 SERPINF1 serine protease inhibitor,clade F Q80ZA3 - ▲ -
S9 PLD2 Phospholipase D2 F1LQD7 ▲ - 5
M1 MBC2 membrane bound C2 domain containing protein Q9Z1X1 ▲ ▲ 5
▲ and 5 symbols indicate the signiﬁcant increase and decrease of each cell activity, respectively (ﬁltered by P value below 0.02). - symbol indicates the
unchanged cell activity.
doi:10.1371/journal.pone.0133845.t001
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interaction data and significance in gene ontology biological processes (GOBPs). The network
model showed that the 23 proteins entirely participated in growth factor receptor tyrosine
kinase and actin cytoskeleton signaling pathways, as well as cellular responses associated with
these signaling pathways, such as cell migration, coagulation, and proliferation-related pro-
cesses (transcription/translation, protein modification, and metabolism). Thus, the network
model supports that our proteome analyses indeed identified the key signaling molecules
essential for the VSMC proliferation and migration. In addition, we found that the two recep-
tor proteins, OLR1 and IL-12Rβ2, do not belong to any of the signaling clusters in the network.
Based on the network analysis, we performed an in vivo validation of novel node proteins in
the pathway clusters using a balloon-induced injury model of rat carotid. To do it, we knocked
down the protein expression by an in vivo transfection of specific siRNAs to the injured lesion
as described in Methods and Materials. The efficacy of the in vivo transfection was tested using
a fluorescent dye-conjugated siRNA (siGLO), suggesting that the siRNA transfection into the
medial SMC layer can be achieved only after a balloon-induced injury (S4A Fig). The in vivo
transfection was further validated by targeting a SMC growth factor receptor PDGFRβ. The
siRNA-mediated knockdown of PDGFRβ in the injured carotid vessels was achieved (S4B and
S4C Fig) and it consequently reduced the neointimal thickening (S4D Fig). Subsequently, we
performed the siRNA-mediated knockdown of the key node proteins (S4E Fig). The knock-
down of each of six proteins (Rab-15, ITR, OLR1, PDHβ, IL-12Rβ2, and PTPε) that had
shown the positive effects on SMC proliferation and migration indeed elicited a significant
reduction in the balloon-induced neointimal thickening (Fig 4A). In contrast, the knockdown
of two proteins (UCH-L1 and PKACA) that had shown the negative effect on the SMC activi-
ties augmented the neointimal thickening (Fig 4B). The knockdown of VDAC1 had no effect
on the neointimal thickening, which may represent a discrepancy between rodent and human
systems.
To elicit a relevance to human vascular disease, we performed immunohistochemistry
(IHC) using carotid arterial sections of human patients with atherosclerotic lesion (Fig 5 and
S5 Fig). The levels of two of the validated proteins (PKACA and PTPε) were increased in the
atherosclerotic lesions by 1.7- and 1.8-fold than those of normal vessel, respectively. This result
confirms that our proteomics screening using a balloon-injured rat model elicited the human-
relevant atherosclerosis target proteins.
OLR1 is a multifaceted signal regulator in human SMCs
We were then particularly interested in the OLR1 known as an endothelial receptor. The func-
tion of OLR1 in VSMCs was unknown although its expression was reported in VSMCs [27].
We first tested whether the OLR1 functions as an oxidized LDL receptor in VSMCs. Treatment
with minimally oxidized LDL (mmLDL) induced the serine phosphorylation-dependent degra-
dation of IκB in VSMCs (Fig 6A) and subsequently enhanced the DNA-binding activity of NF-
κB (Fig 6B). The mmLDL-induced NF-κB activation was completely blocked by the OLR1
knockdown (Fig 6C). These results indicate that VSMCs contain OLR1 as an endogenous oxi-
dized LDL receptor that mediates the NF-κB activation. More importantly, the OLR1 knock-
down inhibited the monocyte adhesion to the VSMCs activated by mmLDLs, which was
completely blocked by a neutralizing antibody against intercellular adhesion molecule-1 (Fig
6D). Considering that the ICAM-dependent monocyte adhesion is crucial for the initiation of
inflammatory response, it is likely that the OLR1 induction in VSMCs by vascular injury may
contribute to the inflammation, thereby exacerbating VSMC hyperplasia.
Since OLR1 played a role in PDGF-induced proliferation and migration, we further exam-
ined the effect of the OLR1 on PDGF signaling. The knockdown of OLR1 expression decreased
OLR1 as a Novel SMCReceptor
PLOS ONE | DOI:10.1371/journal.pone.0133845 August 25, 2015 13 / 23
Fig 4. In vivo functional effect of the depletion of protein candidates on neointimal hyperplasia. The rat carotid arteries were injured and transfected by
a catheter-mediated delivery of the indicated siRNAs as described in the Materials and Methods. After a 10-day recovery, the carotid tissue sections were
prepared and subjected to the histological analyses. Representative HE-stained images are shown. Data in the graph are means ± S.E.M. of intima versus
media ratio measured from HE-stained carotid samples (n = 7 rats per group, *P<0.05, **P<0.01).
doi:10.1371/journal.pone.0133845.g004
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the protein tyrosine phosphorylation including PDGFRβ phosphorylation in response to
PDGF stimulation (Fig 7A). We then hypothesized that OLR1 would function as a co-receptor
for the full activation of PDGFRβ in VSMCs. To test this hypothesis, we explored whether
there is a functional interaction between PDGFRβ and OLR1 in VSMCs. The mmLDL treat-
ment neither induced the PDGFRβ phosphorylation in VSMCs nor interfered with the PDGF-
induced tyrosine phosphorylation (Fig 7B). This result indicates that the mmLDL-OLR1 inter-
action was PDGFRβ-independent. In addition, a slight activation of tyrosine phosphorylation
and ERK kinase by mmLDL alone might be due partly to the formation of hydroxynonenal-
PDGFR adduct [28]. However, the 1-hr pretreatment of mmLDL significantly reduced the
PDGF-induced tyrosine phosphorylation (Fig 7C). In contrast, the 24-hr pretreatment of
mmLDL at various doses had no effect on the PDGF signaling (Fig 7D). It is known that the
scavenger receptors like OLR1 are endocytosed after the ligand engagement [29, 30]. Indeed,
the OLR1 was endocytosed from membrane to cytosolic fraction by 1-hr treatment of
mmLDLs, whereas it was completely recovered in the membrane after 24 hr (Fig 7E). To fur-
ther identify the interaction between OLR1 and PDGFRβ, we performed the proximity ligation
assay using DuoLink. The combination of anti-PDGFRβ and anti-OLR1 antibodies, not the
anti-PDGFRβ antibody alone, showed that OLR1 interacted with PDGFRβ in close proximity
Fig 5. Increased expression of PKACA and PTPε in human carotid arterial sections with atherosclerotic lesions. Immunohistochemistry was
performed using the paraffin-embedded tissue sections of human carotid arteries with thickened intimal lesions (Origin Technologies, Rockville, MD, USA).
The indicated proteins were stained with specific immunohistochemistry-compatible antibodies. Frozen sections of normal peripheral arteries were stained
for control. The 3’,3’-diaminobenzidine (DAB)-stained images are obtained from 5 patient carotid tissue sections and quantified with the HistoFAXS Tissue
Analysis System (TissueGnostics, USA). The expression level is shown as a fold increase of DAB intensities in patient samples versus that in normal vessel.
A representative image with patient identification number is shown. The letter “L” indicates the vascular lumen.
doi:10.1371/journal.pone.0133845.g005
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Fig 6. OLR1 is the oxidized LDL receptor in VSMCs. (A) OxLDL-induced IκB phosphorylation and degradation in VSMCs. The HASMCs were stimulated
with OxLDL (100 μg/ml) for the indicated time periods. (B) OxLDL-induced DNA-binding activity of NF-κB p65 and AP-1 in VSMCs. The DNA-binding activity
was measured using ELISA-based colorimetric TransAM kit (Active Motif, Carlsbad, CA), a 96-well plate with immobilized oligonucleotides encoding NF-κB
or AP-1 consensus binding sequences. Each assay was performed in triplicate and the data in the graph are means ± S.D. of the absorbance units (A450)
from three independent experiments (*P<0.005). (C) OxLDL-induced NF-κB transcriptional activity in VSMCs transfected with control or OLR1 siRNA.
HASMCs were transfected with a NF-κB-dependent luciferase reporter vector followed by siRNA transfection. Cells were incubated in the absence or
presence of OxLDL for 6 hr. The relative luciferase activity was normalized to the β-galactosidase activity and the data in the graph are means ± S.D. of the
luciferase activities from three independent experiments (*P<0.02, **P<0.002). (D) OxLDL-induced monocyte adhesion in VSMCs transfected with control
or OLR1 siRNA. After the siRNA transfection, the HASMCs were stimulated with OxLDL for 24 hr and then preincubated in the presence of isotype control or
anti-CD18 neutralizing antibody before the cell adhesion assay. Representative images are shown and the data in the graph are means ± S.D. of fold change
relative to untreated control cells from three independent experiments (*P<0.01, **P<0.005).
doi:10.1371/journal.pone.0133845.g006
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Fig 7. OLR1 is associated with the PDGF signaling in VSMCs. (A) PDGF-dependent tyrosine phosphorylation in VSMCs transfected with control or OLR1
siRNA. The HASMCs were starved in serum-free culture media for 18 hr and the stimulated with PDGF-BB (25 ng/ml) for the indicated times. The protein
tyrosine phosphorylation was detected using anti-phosphotyrosine antibody (4G10) and the PDGFR activation was measured by immunoblotting the Tyr857
phosphorylation on PDGFRβ. A representative immunoblot is shown (n = 3). (B—D) Effect of OxLDL treatment on PDGF-induced tyrosine phosphorylation in
VSMCs. The serum-starved VSMCs were co-treated with PDGF-BB and OxLDL (B) or pretreated with OxLDL for 1 hr (C) and 24 hr (D) before PDGF-BB
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in the plasma membrane of VSMCs (Fig 7F). Together, these results suggest that the mmLDL-
dependent clearance or genetic depletion of OLR1 from the plasma membrane may dampen
the PDGF-PDGFRβ signaling events in VSMCs.
Discussion
Numerous proteomic and transcriptomic analyses have been carried out in the past decade to
identify biomarkers and target genes related to atherosclerosis. The direct tissue proteomics
using human coronary atherosclerotic plaques have identified several tens of proteins involved
in the plaques, several of which were validated by immunohistochemistry [31]. The Cardio-
Gene study of human patients with in-stent restenosis was designed by the National Heart,
Lung and Blood Institute, NIH (USA) and included proteomics of accessible plasma samples,
not the stent-implanted aortic tissue samples [32]. The rodent models, such as ApoE-deficient
mice fed with high-fat diet or a surgically-induced injury of rat carotid artery, were subjected to
the proteomics and revealed some biomarker candidates and expression profile [33, 34]. How-
ever, we realized that most of these studies have not performed in-depth validation processes.
Therefore, we focused on the multi-layer validation after the quantitative proteomics screening:
1) Use of rodent model for simplicity and reproducibility, 2) In vitro validation using human
aortic VSMCs for human relevance, and 3) Evaluation of functional correlation of the protein
candidates by informatics. Such proteomics and bioinformatics processes produced a list of
candidate proteins that show little overlap with the previous proteomic studies. In particular,
we could select the valuable candidates (e.g. OLR1, PDHβ, and UCHL1) among proteins,
whose expression has been restored to control levels by day 7 after the balloon injury, by the
subsequent in vitro cell assays. Considering that such proteins with a transient expression
change are usually excluded from proteomics study, our study emphasizes the importance of
multi-layer validation steps following the tissue proteomics. Furthermore, some proteins
strongly support the significance of our vascular proteomics work in relation to vascular thick-
ening. For example, ITR was shown to be a G protein-coupled receptor inducing an experi-
mental intimal thickening [35]. PLD2 was indirectly involved in the angiotensin II-induced
neointimal thickening in the balloon-injured artery [36]. Takami et al have shown that
UCH-L1 was highly expressed in the neointima of the balloon-injured carotid artery and was
also detected in atherosclerotic lesions from human carotid arteries [37]. Since most candidate
proteins have not been described in vascular injury or atherosclerosis, we constructed a net-
work model showing functional links between the candidates. The interaction network model
revealed that 23 out of 27 proteins are associated with the growth factor receptor-mediated
actin cytoskeleton reorganization signaling and its related processes: cell migration, coagula-
tion, and proliferation. The network model also offers the insulin-like growth factor-1 (IGF-1)
as one of the most significant extracellular stimuli. In fact, the IGF-1 expression in VSMCs was
shown to associate with insulin insensitivity [38]. The IGF-1 receptor was detected in athero-
sclerotic plaques together with IL-12 and IFNγ [8].
treatment. The activation of MAP kinase ERK was measured by phospho-specific antibody (pTpY). A representative immunoblot is shown (n = 3). (E)
Subcellular distribution of OLR1 in OxLDL-treated VSMCs. Cells were treated with OxLDL (100 μg/ml) for 1 hr or 24 hr and the cell extracts were then
separated to the subcellular fractions by differential centrifugation. A representative immunoblot is shown (n = 3). (F) The proximity ligation assay showing the
OLR1 and PDGFRβ interaction in the plasmamembrane of VSMCs. The proximity ligation assay was performed using DuoLink in situ probes with the
indicated antibodies. DIC and DAPI-stained images are merged with DuoLink fluorescence image (merge). Representative images from two experiments are
shown. (G) OLR1 plays a dual receptor function in VSMCs. OLR1 is expressed in VSMCs and also induced in the arterial vessels by an endothelial
denudation. OLR1 primarily functions as an oxidized LDL receptor in VSMCs that mediates the NF-κB-dependent inflammatory response. OLR1 itself
enhances the PDGF-induced signal transduction including PDGFRβ and ERK phosphorylation. Therefore, the OLR1 is the first SMC receptor that mediates
the pro-inflammatory and proliferative responses in a ligand-dependent and -independent manner, respectively. Purple colored box is a leucine repeat in
OLR1.
doi:10.1371/journal.pone.0133845.g007
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In addition, we studied a novel cellular function of OLR1 in VSMCs because it does not
belong to the growth factor signaling clusters in our network model. Like other scavenger
receptors implicated in the atherosclerosis [5, 16], the OLR1 mediated the OxLDL-induced
NF-κB activation in VSMCs, which in turn augmented the ICAM-dependent monocyte adhe-
sion onto the activated VSMCs. More striking finding is that the depletion or internalization of
the OLR1 impaired the activation of PDGFRβ, a major growth factor receptor of VSMCs. This
evidence suggests a novel function of OLR1 as a potential co-receptor for PDGFRβ, similar to a
co-receptor neuropilin-1 for vascular endothelial growth factor receptor-2 [39]. Thus, it is
likely that OLR1 is the first scavenger receptor that simultaneously coordinates the growth sig-
naling and the inflammatory response in VSMCs (Fig 7G). If this is the case, it is suspected that
a PDGFR-targeted therapy against atherosclerosis and in-stent restenosis may cause a medical
complication in hypercholesterolemia or hyperlipidemia patients [40–43].
In summary, our proteomic screening reveals many potential targets, particularly OLR1, for
vascular diseases with the SMC hyperproliferation.
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S1 Fig. Histology of common carotid arteries after balloon-induced injury in rats. Neointi-
mal thickening was examined during recovery time in balloon-injured carotid artery. Repre-
sentative HE-stained images for normal vessels, 3-day, 7-day, and 14-day post injury are
shown. Arrow indicates the thickened neointimal layer. Data in the graph are means ± SEM of
intima versus media ratio measured from HE-stained carotid samples (n = 4 rats per group).
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S2 Fig. 2D-DIGE and mass spectrometric analyses of protein spots with differential expres-
sion (Related to Fig 1). (A) Typical 2D-DIGE fluorescence images for S-100 cytosolic fraction.
The protein samples from two consecutive time points were differently labeled with Cy3/Cy5
dyes. The internal standard (Std) was labeled with Cy2 dye. (B—D) Quantitative analyses of
the differentially-expressed protein spots on 2D-DIGE gels. The Cy2/Cy3/Cy5 fluorescences
were quantified using the DyCyer software tools in a Typhoon 9400 imager. The amount of
Cy3/Cy5 fluorescence was normalized by that of Cy2 fluorescence and plotted in the histo-
grams. Data in the histogram show the mean ± S.D. of the fold increase of the fluorescence
intensities versus zero time point (n = 3 repeated experiments, P<0.01, P<0.001). The rep-
resentative silver-stained 2D gels for cytosolic (B), nuclei (C), and membrane (D) fractions are
shown. The position of selected protein spots with differential expression are indicated by
arrows with serial spot numbers. The pH gradients and molecular weights are indicated on the
horizontal and vertical axes, respectively. The graphs show. (E) LC-MS/MS spectra. The MS/
MS spectrum of [M + H]+ ions of one of the peptides derived from the indicated protein is
shown. PTPRE, Epsilon tyrosine phosphatase; ANXA2, Annexin A2; F1LRH7, IL-12 receptor
beta 2; HS90B, Hsp90β; A1AT, Serine protease inhibitor 2c; OLR1, Oxidized LDL receptor-1;
G3V799, Intima thickness-related receptor; 1433E, 14-3-3 epsilon; RAB15, Rab-15.
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S3 Fig. Reciprocal regulation of SMC activities by ITR and PKACA. (A) Expression of ITR
and PKACAmRNAs in HASMCs transfected with control or specific siRNAs. Total RNA was
extracted from the HASMC cells using Trizol reagent (Invitrogen) and subjected to a reverse
transcriptase (RT) reaction using ImProm-II reverse transcription system (Promega). The
resulting cDNAs was amplified by PCR using Taq DNA polymerase (Promega) and the PCR
products were visualized by agarose gel electrophoresis and ethidium bromide staining (BIPS
system, Bio-Rad). (B) Negative effect of the ITR knockdown on PDGF-dependent SMC
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proliferation/migration and TNF-α-dependent monocyte adhesion. (C) Positive effect of the
PKACA knockdown on PDGF-dependent SMC proliferation/migration and TNF-α-depen-
dent monocyte adhesion. Each experiment was performed in triplicate and the data in the
graph are means ± S.D. of fold increases from three independent experiments (P<0.01,
P<0.005).
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S4 Fig. Catheter-mediated intramural delivery of siRNA-transfection carrier premixes to
the balloon-injured carotid arteries (Related to Fig 4). (A) In vivo siRNA transfection test.
The fluorescent scrambled siRNA called siGLO (Dharmacon) was introduced into the lumen
of normal or balloon-injured rat common carotid arteries with or without siPORT NeoFX
transfection reagent. Note that the siGLO are transfected to the neointimal cells only when
mixed with transfection reagent in the balloon-injured arteries. Arrow indicates the thickened
neointimal layer. Representative HE-stained and fluorescence images from two independent
experiments are shown. (B and C) In vivo transfection of rat PDGFRβ siRNAs sufficiently
reduces the PDGFRβ expression in rat carotid arteries. The level of PDGFRβ was shown by
immunoblotting (B) and immunofluorescence staining (C). (D) Neointimal thickening in the
balloon-injured carotid artery is reduced by the PDGFRβ knockdown. Representative HE-
stained images are shown. Data in the graph are means ± SEM of intima versus media ratio
measured from HE-stained carotid samples (n = 3 rats per group). (E) Reduction of the target
gene expression in the balloon-injured carotid arteries after the in vivo transfection of specific
siRNAs. Total RNA from carotid vessels was purified using the RNeasy fibrous tissue kit (Qia-
gen). RNA (2 μg) was reverse transcribed using ImProm-II RT system (Promega). The real-
time PCR was performed using specific primers in the presence of SYBR Green (Applied Bio-
systems) inside a fluorescent temperature cycler (ABI Prism 7000 sequence detection system,
Applied Biosystems). The fluorescence signals were quantified by a comparative cycle thresh-
old method. After finishing these cycles, a melting point was checked for specificity. The β-
actin mRNA and 18S rRNA were used as endogenous reference genes. The expression level in
the graph is means ± S.D. of fold changes relative to control-transfected samples (n = 3 rats per
group).
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S5 Fig. Increased expression of PKACA and PTPε in carotid lesions of human patients
with vascular narrowing (Related to Fig 5). Immunohistochemistry was performed using the
paraffin-embedded tissue sections of human carotid arteries with thickened intimal lesions
(Origin Technologies, Rockville, MD, USA). The indicated proteins were stained with specific
immunohistochemistry-compatible antibodies. The 3’,3’-diaminobenzidine (DAB)-stained
images of carotid tissue sections are labeled with patient identification numbers.
(PDF)
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